24 Hospital Avenue Danbury, CT 06810
Donate

Recent Publications

1. Tanamai VW, Seagle BL, Luo G. Methicillin-Resistant Staphyloccocus aureus intracranial Epidural Abscess with Osteomyelitis During Pregnancy: A Case Report. J Reprod Med. 2016 May-Jun;61(5-6):295-8.

2. Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.Eur J Gynaecol Oncol. 2016;37(2):199-203.

3. Ishiguro, K, Zhu, Y.L, Lin, Z.P, Penketh, P.G., Shyam, K, Zhu, R, Baumann, R.P, Sartorelli, A.C, Rutherford, T.J, Ratner, E.S. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian cancer cell lines. 2016 J.Transla. Sci. 2(2):117-124.

4. Seagle BL, Eng KH, Yeh JY, Dandapani M, Schiller E, Samuelson R, Odunsi K, Shahabi S. Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Sci Rep. 2016 Feb 17;6:21591.

5. Dandapani M, Seagle BL, Chacho MS, Shahabi S. Delayed and clinically isolated port site carcinosarcoma recurrence as an early indicator of disseminated disease. Gynecol Oncol Rep. 2015 Sep 1;14:12-5. eCollection 2015 Nov.

6. Seagle BL, Cleason DM, Samuelson R, Shahabi S. Inguinal Node Metastasis of Low-Grade Endometrial Endometrioid Adenocarcinoma in a Morbidly Obese Patient. Conn Med. 2015 Aug;79(7):415-7.

7. Seagle BL, Eng KH, Dandapani M, Yeh JY, Odunsi K, Shahabi S. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget. 2015 Jul 30;6(21):18641-52.

8. Seagle BL, Yang CP, Eng KH, Dandapani M, Odunsi-Akanji O, Goldberg GL, Odunsi K, Horwitz SB, Shahabi S.TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecol Oncol. 2015 Jul;138(1):159-64. doi: 10.1016/j.ygyno.2015.04.039. Epub 2015 May 6.

9. Pasternak, M, Jorgensen, E, Azodi, M, Ratner, E.S., Rutherford, T.J, Santin, A, Schwartz, P.E, Silasi, D.A. Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome. 2015 Gyn Oncol. DOI: 10.1016/j.ygyno.2015.01.184.

10. Roque, D.M, Schwab, C.L, Goloubeva, O, English, D.P, Black, J.D, Silasi, D.A, Azodi, M, Rutherford, T.J, Santin, A, Schwartz, P.E, Ratner, E.S. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. 2015 Gyn Onc. 137:106-107.

11. Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics.Gynecol Obstet Invest. 2015 Jun 6. [Epub ahead of print]

12. Cocco, E, Shapiro, E.M., Gasparrini1, S, Lopez, S, Schwab, C.L., Bellone, S, Bortolomai, I, Sumi, N.J., Bonazzoli, E, Nicoletti, R, Deng, Y, Saltzman, W.M, Zeiss, C.J, Centritto, F, Black, J.D, Silasi, D.A, Ratner, E, Azodi,M, Rutherford, T.J, Schwartz, P.E, Pecorelli, S, and Santin,A.D. Clostidium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micro-metastatic chemotherapy-resistant ovarian cancer: Real-time imaging of ovarian cancer using fluorescent c-CPE. Int J Can. 2015 137(112): DOI:10.1002/ijc.29632

13. Seagle BL, Ballard J, Kakar F, Panarelli E, Samuelson R, Shahabi S. Annual State of Connecticut Obstetrics and Gynecology Resident Research Day. Conn Med. 2015 Jun-Jul;79(6):357-60.

Book Chapters:
1. DeAngelis AM, Roy-O'Reilly M, Rodriguez A. Overview of the Intersection of Genomics of Cholesterol Metabolism and Cardiometabolic Disease with Reproductive Health, Especially in Women. In: Translational Cardiometabolic Genomic Medicine. 1st ed. Academic Press; 2015:251-272


Obstetrics and Gynecology Residency